Psoriasis treatments, particularly systemic therapies like methotrexate, cyclosporin, and TNF inhibitors, carry varying levels of cancer risk, predominantly for non-melanoma skin cancers and lymphoproliferative disorders. Here, TNF is linked to skin neoplasm.